Qualigen, Inc.
2042 Corte Del Nogal
Carlsbad
California
92009
Tel: 760-918-9165
Fax: 760-918-9127
Website: http://www.qualigeninc.com/
Email: info@qualigeninc.com
59 articles about Qualigen, Inc.
-
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
11/7/2023
Qualigen Therapeutics, Inc. announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors.
-
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
8/1/2023
Qualigen Therapeutics, Inc. announces today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s IND application for QN-302, a potential best-in-class small molecule G-Quadruplex (G4)-selective transcription inhibitor.
-
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023
5/16/2023
Qualigen Therapeutics, Inc. today announces financial results for the first quarter ending March 31, 2023, and provides a corporate update.
-
Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
5/2/2023
Qualigen Therapeutics, Inc. announces that two abstracts featuring the Company’s pan-RAS inhibitor program will be included in the American Society of Clinical Oncology’s (ASCO) 2023 Annual Meeting Abstract Book.
-
Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing
4/21/2023
Qualigen Therapeutics, Inc. reports that on April 20, 2023, it received a letter from the Nasdaq Stock Market LLC relating to the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2022 as required under Section 5250 of Nasdaq Rules regarding the Qualification, Listing and Delisting of Companies.
-
Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL
4/18/2023
Qualigen Therapeutics, Inc. today announces data from the Company’s poster presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 held April 14-19 in Orlando, FL.
-
Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
4/18/2023
Qualigen Therapeutics, Inc. today announces data from the Company’s four posters regarding its’ lead program, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023.
-
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
2/1/2023
Qualigen Therapeutics, Inc. today issued the following letter to its stockholders.
-
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
1/23/2023
Qualigen Therapeutics, Inc. today announces the promotion of Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications.
-
Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
1/5/2023
Qualigen Therapeutics, Inc. while also commercializing diagnostics, today shares an update on its majority-owned subsidiary, NanoSynex Ltd. (“NanoSynex”), the progress made during 2022, and objectives for 2023 concerning the commercialization plans for its innovative rapid Antimicrobial Susceptibility Test (AST).
-
Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split - November 22, 2022
11/22/2022
Qualigen Therapeutics, Inc., a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces that its board of directors has approved a 1-for-10 reverse stock split of the Company’s common stock.
-
Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/15/2022
Qualigen Therapeutics, Inc. today announces its financial results for the third quarter ended September 30, 2022, and provides an update on its therapeutic pipeline and other corporate developments.
-
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/16/2022
Qualigen Therapeutics, Inc. today announces its financial results for the second quarter ended June 30, 2022, and provides an update on its therapeutic pipeline and other corporate developments.
-
Qualigen Therapeutics to Present at BIO International Convention
6/14/2022
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics will present a corporate overview at the BIO International Convention to be held on June 13 – 16, 2022 at the San Diego Convention Center.
-
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
5/20/2022
Qualigen Therapeutics, Inc. today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference.
-
Qualigen Therapeutics’ Partner NanoSynex to Present Technology at BioMed Israel
5/10/2022
Qualigen Therapeutics, Inc today announces that NanoSynex Ltd, a company with whom Qualigen recently entered into definitive agreements to acquire a majority stake, will be featured at BioMed Israel on May 11, 2022. BioMed Israel is being held at David InterContinental Hotel in Tel Aviv May 10-12, 2022.
-
Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results
4/1/2022
Qualigen Therapeutics, Inc. today announces its financial results for the fiscal year ended December 31, 2021.
-
Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders
2/22/2022
Qualigen Therapeutics, Inc. today issues the following Letter to Shareholders:
-
Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
12/1/2021
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain institutional investors for the purchase and sale of 5,880,000 shares of common stock for $1.50 per share (i.e., for aggregate gross proceeds of $8,820,000).
-
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
9/15/2021
Qualigen Therapeutics, Inc. announced today that CEO and Chairman Michael Poirier will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 20-23, 2021.